Codony-Servat et al. found that EGFR inhibition activated Notch signaling and thus induced the outgrowth of tumor stem cells and that the efficacy of EGFR-targeted therapy diminished in tumors with high HES1 expression (Codony-Servat et al., 2019). The gene discussed is EGFR; the disease is neoplasm.